Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

医学 转甲状腺素 安慰剂 多发性神经病 内科学 淀粉样变性 生活质量(医疗保健) 临床终点 物理疗法 随机对照试验 外科 病理 护理部 替代医学
作者
Teresa Coelho,Wilson Marques,Noel R. Dasgupta,Chi‐Chao Chao,Yeşim Parman,Marcondes C. França,Yuh‐Cherng Guo,Jonas Wixner,Long‐Sun Ro,Cristian Calandra,Pedro André Kowacs,John L. Berk,Laura Obici,Fabio Barroso,Markus Weiler,Isabel Conceição,Shiangtung W. Jung,Gustavo Büchele,Michela Brambatti,Jersey Chen,Steven G. Hughes,Eugene Schneider,Nicholas J. Viney,Ahmad Masri,Morie R. Gertz,Yukio Ando,Julian D. Gillmore,Sami Khella,P. James B. Dyck,Márcia Waddington‐Cruz,Anna Mazzeo,Aikaterini Papagianni,Mazen M. Dimachkie,Ioannis Zaganas,Edward Gane,Marco Luigetti,Lucía Galán Dávila,Michelle M. Mezei,Juan González Moreno,Pascal Cintas,Davide Pareyson,Rebecca Traub,Julie Khoury,Conrado J. Estol,Merrilee Needham,David Adams,Michael Polydefkis,Thomas H. Brannagan,Vera Bril,Shahram Attarian,Marcelo Rugiero,B. Jane Distad,Eleni Zamba Papanicolaou,Kon‐Ping Lin,Merrill D. Benson,Morton Scheinberg
出处
期刊:JAMA [American Medical Association]
卷期号:330 (15): 1448-1448 被引量:27
标识
DOI:10.1001/jama.2023.18688
摘要

Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group. Interventions Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P < .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P < .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P < .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
BINBIN完成签到 ,获得积分10
8秒前
快乐的幼丝完成签到 ,获得积分10
11秒前
求助完成签到,获得积分0
20秒前
黯然完成签到 ,获得积分10
29秒前
缺粥完成签到 ,获得积分10
35秒前
烂漫的蜡烛完成签到 ,获得积分10
39秒前
宇文非笑完成签到 ,获得积分10
41秒前
白桃完成签到 ,获得积分10
1分钟前
qaplay完成签到 ,获得积分0
1分钟前
快乐小恬完成签到 ,获得积分10
1分钟前
janer完成签到 ,获得积分10
1分钟前
小蘑菇应助贪玩的笑阳采纳,获得10
1分钟前
1分钟前
和平使命应助科研通管家采纳,获得10
1分钟前
和平使命应助科研通管家采纳,获得10
1分钟前
1分钟前
爱爱完成签到 ,获得积分10
1分钟前
牟翎发布了新的文献求助30
1分钟前
清修完成签到,获得积分10
1分钟前
MADAO完成签到 ,获得积分10
1分钟前
科研张完成签到 ,获得积分10
1分钟前
小卷粉完成签到 ,获得积分10
2分钟前
Johnson完成签到 ,获得积分10
2分钟前
玛卡巴卡完成签到 ,获得积分10
2分钟前
cadcae完成签到,获得积分10
2分钟前
危机的道天完成签到 ,获得积分10
2分钟前
eternal_dreams完成签到 ,获得积分10
2分钟前
活力的泥猴桃完成签到 ,获得积分10
2分钟前
紫熊完成签到,获得积分10
2分钟前
苏云墨完成签到 ,获得积分10
2分钟前
风趣的冬卉完成签到 ,获得积分10
2分钟前
木林森林木完成签到 ,获得积分10
2分钟前
温暖糖豆完成签到 ,获得积分10
2分钟前
先锋老刘001完成签到,获得积分10
3分钟前
华理附院孙文博完成签到 ,获得积分10
3分钟前
Zz完成签到 ,获得积分10
3分钟前
研友_ZA2B68完成签到,获得积分10
3分钟前
机智的从霜完成签到 ,获得积分10
3分钟前
Gary完成签到 ,获得积分10
4分钟前
4分钟前
高分求助中
Earth System Geophysics 1000
Co-opetition under Endogenous Bargaining Power 666
Medicina di laboratorio. Logica e patologia clinica 600
Handbook of Marine Craft Hydrodynamics and Motion Control, 2nd Edition 500
Sarcolestes leedsi Lydekker, an ankylosaurian dinosaur from the Middle Jurassic of England 500
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
Language injustice and social equity in EMI policies in China 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3213154
求助须知:如何正确求助?哪些是违规求助? 2861948
关于积分的说明 8131363
捐赠科研通 2527909
什么是DOI,文献DOI怎么找? 1361934
科研通“疑难数据库(出版商)”最低求助积分说明 643561
邀请新用户注册赠送积分活动 615885